CA-4948
| 中文名稱 | CA-4948 |
|---|---|
| 中文同義詞 | 6'-AMINO-N-[2-(4-MORPHOLINYL)OXAZOLO[4,5-B]PYRIDIN-6-YL][2,3'-BIPYRIDINE]-6-CARBOXAMIDE;化合物CA-4948;6'-氨基-N-[2-(嗎啉-4-基)-[1,3]惡唑并[4,5-B]吡啶-6-基]-[2,3'-聯(lián)吡啶]-6-甲酰胺;IRAK4-IN-2;PERFEMIKER]CA-4948,99%;CA-4949;化合物CA-4948,10 MM DMSO 溶液;1801343-74-7;CA-4948 |
| 英文名稱 | CA-4948 |
| 英文同義詞 | CA-4948;CA 4948, CA-4948, CA4948;IRAK4-IN-7;CA 4948;CA4948;6'-Amino-N-[2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl][2,3'-bipyridine]-6-carboxamide;[2,3'-Bipyridine]-6-carboxamide, 6'-amino-N-[2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl]-;CA4948-Analog;IRAK4-IN-7 (CA4948 analog) |
| CAS號 | 1801343-74-7 |
| 分子式 | C21H19N7O3 |
| 分子量 | 417.42 |
| EINECS號 | |
| 相關(guān)類別 | 抑制劑 |
| Mol文件 | 1801343-74-7.mol |
| 結(jié)構(gòu)式 |  |
CA-4948 性質(zhì)
| 熔點 | >294°C (dec.) |
|---|---|
| 密度 | 1.444±0.06 g/cm3(Predicted) |
| 儲存條件 | -20°C Freezer, Under inert atmosphere |
| 溶解度 | 可溶于DMSO（少許）、甲醇（少許） |
| 酸度系數(shù)(pKa) | 10.41±0.43(Predicted) |
| 形態(tài) | 固體 |
| 顏色 | 淡黃色至棕色油狀 |
| InChI | InChI=1S/C21H19N7O3/c22-18-5-4-13(11-23-18)15-2-1-3-16(26-15)20(29)25-14-10-17-19(24-12-14)27-21(31-17)28-6-8-30-9-7-28/h1-5,10-12H,6-9H2,(H2,22,23)(H,25,29) |
| InChIKey | RWIMETUXCNDSLE-UHFFFAOYSA-N |
| SMILES | C1(C2=CC=C(N)N=C2)=NC(C(NC2=CN=C3N=C(N4CCOCC4)OC3=C2)=O)=CC=C1 |
IRAK4-IN-2 是一種可逆性激酶抑制劑，在TLR和IL-1R信號級聯(lián)反應中，調(diào)節(jié)IRAK4的功能。
CA-4948 is a potent, and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. CA-4948 exhibited the greatest efficacy in four of the five ABC-DLBCL PDX models tested as compared to GBC-DLBCL and ABC/GCB DLBCL PDX models. Furthermore, CA-4948 was efficacious in ABC-DLBCL PDX tumors containing activating mutations in both TLR/IL-1R and BCR signaling pathways (MYD88 and CD79B double mutants).
| Target | Value |
|
IRAK4
() |
用途
一種可逆性激酶抑制劑，在TLR和IL-1R信號級聯(lián)反應中，調(diào)節(jié)IRAK4的功能。在體內(nèi)外實驗中，具有良好的藥代動力學特征和抗腫瘤活性。CA-4948 is a potent, and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. CA-4948 exhibited the greatest efficacy in four of the five ABC-DLBCL PDX models tested as compared to GBC-DLBCL and ABC/GCB DLBCL PDX models. Furthermore, CA-4948 was efficacious in ABC-DLBCL PDX tumors containing activating mutations in both TLR/IL-1R and BCR signaling pathways (MYD88 and CD79B double mutants).
安全信息
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-109585 | CA-4948 IRAK4-IN-7 | 1801343-74-7 | 5mg | 900元 |
| 2026/06/05 | HY-109585 | CA-4948 IRAK4-IN-7 | 1801343-74-7 | 10mM * 1mLin DMSO | 990元 |